Patent ID: 6117895
Filing Date: 2000-09-12
Classification: A61K,A61P

Abstract:
A method of treating a disease mediated by activation of the tumor necrosis factor, comprising administering to a patient in need of such treatment an amount effective to inhibit TNF or its production of an optically active or racemic compound of formula ##STR3## in which R.sup.1 is C.sub.1-4 alkyl,R.sup.2 is C.sub.1-6 alkyl, C.sub.3-7 cycloalkyl, C.sub.3-7 cycloalkyl-C.sub.1-2 alkyl, C.sub.2-6 alkenyl, C.sub.3-7 alkynyl, a 5- or 6-membered, saturated heterocycle, or a C.sub.1-6 alkyl substituted with one or more of halogen, hydroxy, carboxy, C.sub.1-4 alkoxy, C.sub.1-4 alkoxy-carbonyl or an amino group that is optionally substituted with C.sub.1-4 alkyl,R.sup.3 is hydrogen, C.sub.1-6 alkyl, acyl, C.sub.6-10 -aryl, C.sub.6-10 -aralkyl, or C.sub.6-10 -aryl substituted with 1 or 2 methyl groups andR.sup.4 is hydrogen or C.sub.1-6 alkyl,with the proviso that said compound is not administered locally to treat inflammation.